At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RXRX Recursion Pharmaceuticals, Inc.
Not Yet Opened 12-17 16:00:00 EST
4.68
+0.48
+11.43%
盘后4.83
+0.15+3.27%
19:59 EST
High5.01Low4.48Vol65.55M
Open4.51D1 Closing4.20Amplitude12.62%
Mkt Cap2.43BTradable Cap1.94BTotal Shares519.84M
T/O315.75MT/O Rate15.80%Tradable Shares415.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Cathie Wood's Big Crypto Bet: Ark Scoops up Bitmine, Coinbase and Bullish, Dumps This Amazon Rival
Benzinga  ·  11:45
Cathie Wood's Big Crypto Bet: Ark Scoops up Bitmine, Coinbase and Bullish, Dumps This Amazon Rival
Recursion Pharmaceuticals Shares Rise After JPMorgan Upgrade
MT Newswires Live  ·  03:57
Recursion Pharmaceuticals Shares Rise After JPMorgan Upgrade
Recursion Pharmaceuticals Rises 13.1% After JP Morgan Raises Co to 'Overweight' From 'Neutral'
THOMSON REUTERS  ·  12-17 23:17
Recursion Pharmaceuticals Rises 13.1% After JP Morgan Raises Co to 'Overweight' From 'Neutral'
JPMorgan Upgrades Recursion Pharmaceuticals to Overweight From Neutral, Adjusts PT to $11 From $10
MT Newswires Live  ·  12-17 21:09
JPMorgan Upgrades Recursion Pharmaceuticals to Overweight From Neutral, Adjusts PT to $11 From $10
Why Are Shares Of Recursion Pharmaceuticals Higher Today?
Benzinga_recent_news  ·  12-08
Why Are Shares Of Recursion Pharmaceuticals Higher Today?
Recursion Pharmaceuticals Shares up 6.1% After Co's Experimental Therapy Reduces Polyp Growth in Rare Disease Trial
THOMSON REUTERS  ·  12-08
Recursion Pharmaceuticals Shares up 6.1% After Co's Experimental Therapy Reduces Polyp Growth in Rare Disease Trial
BUZZ-Recursion climbs as experimental drug reduces polyp growth in rare disease trial
Reuters  ·  12-08
BUZZ-Recursion climbs as experimental drug reduces polyp growth in rare disease trial
Recursion Reports Positive Phase 2 Results for REC-4881 in Familial Adenomatous Polyposis
Reuters  ·  12-08
Recursion Reports Positive Phase 2 Results for REC-4881 in Familial Adenomatous Polyposis
BRIEF-Recursion's Tupelo Trial Phase 1B/2 Results Show Polyp Burden Reductions In FAP At 25 Weeks
Reuters  ·  12-08
BRIEF-Recursion's Tupelo Trial Phase 1B/2 Results Show Polyp Burden Reductions In FAP At 25 Weeks
Recursion: to Expand Population From ≥55 to ≥18 Years Old & Further Optimize Dosing Schedule for Rec-4881
THOMSON REUTERS  ·  12-08
Recursion: to Expand Population From ≥55 to ≥18 Years Old & Further Optimize Dosing Schedule for Rec-4881
Recursion: to Engage FDA in 1H26 to Define Potential Registration Pathway for Rec-4881
THOMSON REUTERS  ·  12-08
Recursion: to Engage FDA in 1H26 to Define Potential Registration Pathway for Rec-4881
Recursion: 82% of Evaluable Patients of Rec-4881 Tupelo Trial Maintained Reductions at Week 25, With 53% Median Decrease From Baseline
THOMSON REUTERS  ·  12-08
Recursion: 82% of Evaluable Patients of Rec-4881 Tupelo Trial Maintained Reductions at Week 25, With 53% Median Decrease From Baseline
Recursion: Rec-4881 Tupelo Trial Phase 1B/2 Results Show Rapid & Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis at 25 Weeks
THOMSON REUTERS  ·  12-08
Recursion: Rec-4881 Tupelo Trial Phase 1B/2 Results Show Rapid & Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis at 25 Weeks
Recursion: Rec-4881 Has Safety Profile Consistent With Mek1/2 Inhibition
THOMSON REUTERS  ·  12-08
Recursion: Rec-4881 Has Safety Profile Consistent With Mek1/2 Inhibition
Recursion Pharmaceuticals CEO Christopher Gibson Reports Sale of Common Shares
Reuters  ·  12-06
Recursion Pharmaceuticals CEO Christopher Gibson Reports Sale of Common Shares
Jim Cramer: This Health Care Stock Has Been 'Horrendous'
Benzinga_recent_news  ·  12-05
Jim Cramer: This Health Care Stock Has Been 'Horrendous'
Recursion Pharmaceuticals Director Blake Borgeson Reports Disposal of Common Shares
Reuters  ·  12-05
Recursion Pharmaceuticals Director Blake Borgeson Reports Disposal of Common Shares
Miss These Genesis Mission Stocks, and You’ll Regret It for a Decade
InvestorPlace  ·  12-02
Miss These Genesis Mission Stocks, and You’ll Regret It for a Decade
Recursion Shares Down 3.7% Premarket Ahead of Early-Mid Stage Trial Data for Genetic Disorder Drug
THOMSON REUTERS  ·  12-01
Recursion Shares Down 3.7% Premarket Ahead of Early-Mid Stage Trial Data for Genetic Disorder Drug
Recursion Pharmaceuticals Announces New Clinical Data Readout for REC-4881 in Familial Adenomatous Polyposis
Reuters  ·  12-01
Recursion Pharmaceuticals Announces New Clinical Data Readout for REC-4881 in Familial Adenomatous Polyposis

Introduction

Company Name.
Recursion Pharmaceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Issue price:
--